Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors |
| |
Authors: | Xia Dajing Moyana Terence Xiang Jim |
| |
Affiliation: | Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada. |
| |
Abstract: | Recent developments in tumor immunology and biotechnology have made cancer gene therapy and immunotherapy feasible.The current efforts for cancer gene therapy mainly focus on using immunogenes,chemogenes and tumor sup- pressor genes.Central to all these therapies is the development of efficient vectors for gene therapy.By far,adenovirus (AdV)-mediated gene therapy is one of the most promising approaches,as has confirmed by studies relating to animal tumor models and clinical trials.Dendritic cells (DCs) are highly efficient,specialized antigen-presenting cells,and DC- based tumor vaccines are regarded as having much potential in cancer immunotherapy.Vaccination with DCs pulsed with tumor peptides,Iysates,or RNA,or loaded with apoptotic/necrotic tumor cells,or engineered to express certain cytokines or chemokines could induce significant antitumor cytotoxic T lymphocyte (CTL) responses and antitumor immunity.Although both AdV-mediated gene therapy and DC vaccine can both stimulate antitumor immune responses, their therapeutic efficiency has been limited to generation of prophylactic antitumor immunity against re-challenge with the parental tumor cells or to growth inhibition of small tumors.However,this approach has been unsuccessful in com- bating welt-established tumors in animal models.Therefore,a major strategic goal of current cancer immunotherapy has become the development of novel therapeutic strategies that can combat welt-established tumors,thus resembling real clinical practice since a good proportion of cancer patients generally present with significant disease.In this paper,we review the recent progress in AdV-mediated cancer gene therapy and DC-based cancer vaccines,and discuss combined immunotherapy including gene therapy and DC vaccines.We underscore the fact that combined therapy may have some advantages in combating well-established tumors vis-a-vis either modality administered as a monotherapy. |
| |
Keywords: | gene therapy adenovirus dendritic cells vaccine cytotoxic T lymphocytes antitumor immunity |
本文献已被 CNKI 维普 PubMed 等数据库收录! |
|